Research at Oxford University’s Institute of Molecular Medicine has identified a novel therapeutic regimen for the treatment of cancer that provides significant advantages over the existing methods of cancer treatment.
There are already a number of regimens available for treatment of cancer, including chemotherapy, which is commonly used to treat a number of different types of cancer. In most cases chemotherapeutic agents are given at the maximum tolerated dose (MTD), but at such doses the treatments can only be given in short courses and often have unacceptable side effects. In recent years, the use of immunotherapy for tumours has also increased, but tumour cells have been shown to evade immunotherapy by mutating to avoid presentation of the specific tumour epitope to the immune system. It has previously been suggested that a combination of immunotherapy and chemotherapy may prove effective as a treatment. However, this has not proved ideal since conventional chemotherapy suppresses the immune system, thereby reducing the effectiveness of the immunotherapy.
Researchers in Oxford have now devised a novel therapeutic regimen that combines the advantages of both chemotherapy and immunotherapy whilst reducing the disadvantages of each. It has been shown that chemotherapeutic agents can have a beneficial effect at doses lower than the MTD (such a dosing regimen has become known as metronomic dosing). Metronomic dosing, whilst not being as aggressive as the MTD regimen, has fewer side effects and can be used for longer periods without a break. The researchers have identified a metronomic regimen that does not cause the severe immunosuppression of standard chemotherapy and so opens the possibility of combining immunotherapy and chemotherapy. Furthermore, they have shown that such a combination therapy is more effective at inhibiting tumour growth than either chemotherapy (at MTD or as a metronomic dose), or immunotherapy alone or than immunotherapy in combination with chemotherapy at MTD.
Jennifer Johnson | alfa
PET imaging tracks Zika virus infection, disease progression in mouse model
20.09.2017 | US Army Medical Research Institute of Infectious Diseases
'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton
Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...
Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
20.09.2017 | Life Sciences
20.09.2017 | Power and Electrical Engineering
20.09.2017 | Physics and Astronomy